Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as ge...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

ERPBlast Mar. 13 at 11:36 AM

$CGTX wher is big news? Febraury and the first week of March are already over.

0 · Reply

Dmsrz8 Mar. 12 at 9:18 PM

$CGTX annual report came out last year on 3/20, so we should see something soon in regard to that. Been very quiet the last few weeks so I’m interested to see if there is anything else to the story that would benefit us shareholders

0 · Reply

Aimforsuccess Mar. 12 at 3:32 PM

$CGTX Financial terrorists at it again?

1 · Reply

PERUSIA Mar. 12 at 3:14 PM

$CGTX It repeats between 1 and 1.18

1 · Reply

nostic Mar. 12 at 2:59 PM

$CGTX haven't seen any announcement, but last year the Q4 ER was on March 20 I believe.

0 · Reply

SharkLips Mar. 12 at 2:57 PM

$CGTX ⌛️

0 · Reply

ERPBlast Mar. 12 at 2:30 PM

$CGTX hehe back to the future part 3 McFly

0 · Reply

Dmsrz8 Mar. 12 at 1:12 PM

$CGTX pee-market volume of 2800 shares traded is nothing. Hoping for some continuation of the positive momentum of the last few days

0 · Reply

PERUSIA Mar. 12 at 12:44 AM

$CGTX When is the earnings announcement?

0 · Reply

Dmsrz8 Mar. 11 at 2:30 PM

$CGTX go ahead and break upwards! You know you want to

0 · Reply

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Feb 5, 2026, 7:30 AM EST - 5 weeks ago

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Jan 27, 2026, 7:30 AM EST - 6 weeks ago

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Jan 6, 2026, 7:30 AM EST - 2 months ago

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

Dec 1, 2025, 7:30 AM EST - 3 months ago

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 20, 2025, 4:01 PM EST - 4 months ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 13, 2025, 7:36 AM EST - 4 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

Nov 6, 2025, 7:30 AM EST - 4 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

Sep 3, 2025, 7:30 AM EDT - 6 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Sep 2, 2025, 4:00 PM EDT - 6 months ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

Aug 27, 2025, 8:53 PM EDT - 7 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

Aug 26, 2025, 4:00 PM EDT - 7 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 26, 2025, 10:08 AM EDT - 7 months ago

Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating

Aug 12, 2025, 4:00 PM EDT - 7 months ago

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

Jul 29, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Jul 21, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

Jul 16, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 10, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

Jul 1, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Jun 25, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 10 months ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 10 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 1:15 PM EDT - 1 year ago

Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 1 year ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 1 year ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 11:06 AM EST - 1 year ago

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Dec 18, 2024, 7:22 AM EST - 1 year ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 1 year ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 29, 2024, 12:55 PM EDT - 1 year ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Aug 22, 2024, 7:31 AM EDT - 1 year ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Aug 11, 2024, 12:55 AM EDT - 1 year ago

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

ERPBlast Mar. 13 at 11:36 AM

$CGTX wher is big news? Febraury and the first week of March are already over.

0 · Reply

Dmsrz8 Mar. 12 at 9:18 PM

0 · Reply

Aimforsuccess Mar. 12 at 3:32 PM

$CGTX Financial terrorists at it again?

1 · Reply

PERUSIA Mar. 12 at 3:14 PM

$CGTX It repeats between 1 and 1.18

1 · Reply

nostic Mar. 12 at 2:59 PM

$CGTX haven't seen any announcement, but last year the Q4 ER was on March 20 I believe.

0 · Reply

SharkLips Mar. 12 at 2:57 PM

$CGTX ⌛️

0 · Reply

ERPBlast Mar. 12 at 2:30 PM

$CGTX hehe back to the future part 3 McFly

0 · Reply

Dmsrz8 Mar. 12 at 1:12 PM

$CGTX pee-market volume of 2800 shares traded is nothing. Hoping for some continuation of the positive momentum of the last few days

0 · Reply

PERUSIA Mar. 12 at 12:44 AM

$CGTX When is the earnings announcement?

0 · Reply

Dmsrz8 Mar. 11 at 2:30 PM

$CGTX go ahead and break upwards! You know you want to

0 · Reply

easydollars1 Mar. 11 at 1:47 PM

$CGTX still here little busy with options 😊. Profits coming here shortly

1 · Reply

dkempire Mar. 11 at 1:44 PM

$CGTX pt 12

1 · Reply

DiamondHands4daWin Mar. 11 at 5:09 AM

$CGTX - Reposting for those who just joined us. Welcome.

1 · Reply

antiossidan Mar. 10 at 8:40 PM

$CGTX what do you think about Relay stock? News on 16 march

1 · Reply

agarfield Mar. 10 at 6:32 PM

$CGTX price movements aren't worth reading into until we get insight into where funding is coming from, which hopefully comes from a well negotiated partnership with pathway to buyout. The FDA's DLB response gives them a good negotiating floor to work with (the Dry AMD aspect is a huge selling point as well, that would be nice to get funded and get going ASAP). That will set the price floor here to around 3 while next steps begin. Anything less just adds more time it takes to get to market.

1 · Reply

Dmsrz8 Mar. 10 at 5:43 PM

$CGTX could break tha 1.20 area…only around 500k volume so far which is not a lot of pressure. I want to see PRESSURE! Push on this and let’s see what occurs

0 · Reply

nostic Mar. 10 at 5:29 PM

$CGTX damn! 385k share bid at $1.04 on Level 2. To me, that's a protective move as we wait for news on the Strategic Oil Reserve decision. In short, someone is acting to prevent a fall below $1.00, and/or is happy to accumulate substantial shares around $1.00.

0 · Reply

GibsonFlyingV Mar. 10 at 5:12 PM

$CGTX holding what I got. Never any doubt.

0 · Reply

dkempire Mar. 10 at 5:05 PM

$BBAI $CGTX $VERI $WDH

0 · Reply

nostic Mar. 10 at 4:10 PM

$CGTX need to break above $1.21 to really fly, but getting there.

0 · Reply

Marshallmathers1 Mar. 10 at 3:59 PM

$CGTX Lots of buying. Hope the trend continues. Still holding 44k shares. Not selling shit. lol

1 · Reply

Dmsrz8 Mar. 10 at 3:01 PM

$CGTX volume is only 286k traded which is not a lot. Good to see it going up, however

1 · Reply

Market Cap	92.69M
Revenue (ttm)	0.00
Net Income (ttm)	-33.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	405,300
Avg Vol	835,070
Day's Range	N/A - N/A
Shares Out	88.27M
Stochastic %K	28%
Beta	1.25
Analysts	Strong Sell
Price Target	$3.50